Elan filed the patent litigation case against Abraxis BioScience in 2006, which was acquired by Celgene in October 2010.
In consideration of the terms of the settlement and license agreement, Celgene will pay Elan a one-time fee of $78m.
Further, Elan will not receive any additional payments for sales of Abraxane, or any other nab-Paclitaxel product in the US or globally.
Celgene will take over a fully-paid up, exclusive, world-wide license to select Elan US and foreign patents for Abraxane.